Nehad Soloman

Sep 20, 2024 | hcplive.com | Nehad Soloman |Andrew Sharobeem |Sunil Patel

Moving Beyond the Joint: The Interplay Between Gout and Kidney Disease Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

Sep 6, 2024 | hcplive.com | Nehad Soloman |Andrew Sharobeem |Sunil Patel

Moving Beyond the Joint: The Interplay between Gout and Kidney Disease Nehad Soloman, MD, FACR; Andrew Sharobeem, DO, FACR, and Sunil Patel, MD, explore the nephrologist's vital role in gout diagnosis, treatment options for gout patients with chronic kidney disease, and strategies for managing refractory gout and its associated challenges.

Dec 6, 2023 | hcplive.com | Nehad Soloman |Andrew Sharobeem |Daniel Wallace

0:00 Introduction 1:25 LN and its prognosis 3:20 Challenges due to varied presentations of LN 4:10 Traditional treatment paradigms 6:45 Challenges with management of LN 8:25 Classification of LN and its role in treatment 12:00 New treatments in LN 17:50 Anti-CD20 for treatment of LN 21:00 Combination therapy in clinical practice 22:45 Multidisciplinary care for LN 23:50 Guidelines in LN 26:00 Kidney biopsy in LN 27:15 Biomarkers for LN 28:30 Clinical outcomes in LN 31:30 JAK inhibitors in...

Nov 17, 2023 | hcplive.com | Nehad Soloman |Andrew Sharobeem |Vibeke Strand

0:00 Introduction 01:29 Precision Medicine in Rheumatoid Arthritis (RA) 03:34 Biomarkers and Diagnostic Tools in RA 07:08 Science Behind Molecular Signature Response Classifier (MSRC) Test 08:30 Accelerate Information of Molecular Signatures (AIMS) Study 10:33 Experience with MSRC Test in Clinical Practice 12:46 Heterogeneity of RA and Development of Other Biomarkers in RA 14:49 MSRC Test Coverage by Medicare and Future of Precision Medicine in RA 17:54 Safe Step Act in RA Management and...

Oct 10, 2023 | hcplive.com | Nehad Soloman |Andrew Sharobeem |Philip Mease

00:00 Welcome and introductions01:40 Novel therapeutic agents targeting pathophysiology of rheumatic diseases06:15 IL-17A, IL-17F inhibitor bimekizumab07:42 Tyk2 inhibitor deucravacitnib in rheumatology09:50 IL-17A inhibitor izokibep in psoriatic arthritis11:10 Outcome measures in rheumatic diseases16:20 Molecular signature response classifier (MSRC) test19:40 Biosimilars in rheumatology24:30 Precision medicine in clinical practice29:30 Role of advanced practice practitioners in rheumatology